Work-up for Malignant Effusion
Begin with ultrasound-guided thoracentesis to obtain pleural fluid for cytology, as this is the simplest definitive method for diagnosing malignant pleural effusion and should be performed in all patients with accessible effusions 1.
Initial Diagnostic Approach
Imaging
- CT chest with IV contrast is the gold standard for evaluating suspected malignant pleural effusion, particularly when there is increased pretest probability of malignancy 2
- Acquire the CT scan 60 seconds after contrast bolus to optimize visualization of pleural abnormalities 2
- Look specifically for pleural thickening, pleural nodules/masses, and mediastinal involvement on imaging 1
Thoracentesis Technique and Fluid Analysis
Ultrasound guidance is strongly recommended as it improves success rates and decreases pneumothorax risk 1. Send pleural fluid for:
- Cytology (diagnostic yield 60-90% depending on tumor type) 3, 4
- Cell count with differential
- Total protein and LDH (to confirm exudate)
- Glucose and pH
- Amylase (if appropriate clinical suspicion)
Critical interpretation points:
- Approximately 97% of malignant effusions are exudates, but 3% can be transudates 3, 5
- Lymphocyte predominance is typical but not required 3
- pH <7.30 and glucose <60 mg/dL suggest higher tumor burden and predict worse survival (median 2.1 months vs 9.8 months) 3, 4
- Elevated amylase (salivary isotype) strongly suggests malignancy, most commonly lung adenocarcinoma 3
If Initial Cytology is Negative
Do not stop at one negative cytology result. The diagnostic algorithm proceeds as follows:
Repeat thoracentesis - A second sample increases diagnostic yield by 27% (from 65% to 92% cumulative) 1, 4
If CT shows pleural thickening or nodules, proceed directly to image-guided pleural biopsy rather than blind biopsy 1
If pleural thickening is absent, perform pleural biopsy via medical thoracoscopy or surgical thoracoscopy (VATS) 1, 3
Important caveat: Blind percutaneous pleural biopsies have poor sensitivity (40-75%) and only diagnose an additional 7-12% of cases when cytology is negative 3. They should be reserved for situations where thoracoscopy is unavailable or contraindicated.
Special Considerations
Mesothelioma
- Cytology has lower sensitivity (58%) compared to other malignancies 3
- CT-guided biopsy is preferred when pleural abnormalities are visible 3
- Immunohistochemistry is essential: use CEA, calretinin, and cytokeratin 5/6 to distinguish from adenocarcinoma 4
Adenocarcinoma vs Mesothelial Cells
When differentiation is problematic, use immunohistochemical staining:
- Adenocarcinoma markers: CEA (50-90% positive), Leu-1, mucin, EMA 3, 4
- Mesothelial markers: Calretinin, cytokeratin 5/6 (0-10% positive in adenocarcinoma) 4
Molecular Testing
Obtain adequate tissue for molecular profiling when targeted therapy is being considered:
- EGFR mutation testing in lung adenocarcinoma has prognostic and therapeutic implications 6
- Large tissue samples from pleural biopsy are increasingly necessary rather than cytology alone 7
Common Pitfalls to Avoid
Do not assume transudative biochemistry excludes malignancy - 3% of confirmed malignant effusions are transudates, often due to concomitant heart failure or lymphatic obstruction 3, 5
Do not perform bronchoscopy routinely in the workup of undiagnosed effusion unless the patient has hemoptysis or radiographic evidence of bronchial obstruction 4
Do not rely on pleural fluid pH alone for prognosis or treatment decisions - use it in conjunction with performance status, tumor type, and overall clinical picture 3
Do not delay thoracoscopy in patients with high clinical suspicion and negative initial tests - waiting for multiple negative cytologies prolongs diagnosis without significantly improving yield 3